AKR1C1 overexpression leads to lenvatinib resistance in hepatocellular carcinoma
Journal of Gastrointestinal Oncology · 2023-06 · 14 (3) · 1412-1433
DOI: 10.21037/jgo-23-277 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastrointestinal Oncology, 2023-06. Verfasst von Cheng Gao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, China. Die Arbeit wurde bisher 13-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of General Surgery, Affiliated Hospital of Nantong University, Medical School of Nantong University, Nantong, China.
- Department of General Surgery, Affiliated Hospital of Nantong University, Nantong, China.
Zitieren
APA
Gao, C., Chang, L., Xu, T., Li, X., & Chen, Z. (2023). AKR1C1 overexpression leads to lenvatinib resistance in hepatocellular carcinoma. Journal of Gastrointestinal Oncology, 14(3), 1412-1433. https://doi.org/10.21037/jgo-23-277
Vancouver
Gao C, Chang L, Xu T, Li X, Chen Z. AKR1C1 overexpression leads to lenvatinib resistance in hepatocellular carcinoma. Journal of Gastrointestinal Oncology. 2023;14(3):1412-1433. doi:10.21037/jgo-23-277
BibTeX
@article{Gao2023,
author = {Gao, Cheng and Chang, Liang and Xu, Tianxin and Li, Xiaojun and Chen, Zhong},
title = {AKR1C1 overexpression leads to lenvatinib resistance in hepatocellular carcinoma},
journal = {Journal of Gastrointestinal Oncology},
year = {2023},
volume = {14},
number = {3},
pages = {1412--1433},
doi = {10.21037/jgo-23-277}
}
EUVIMED